Content
All Posts > Content under Healthcare
Tocagen IPO Could Garner Significant Investor Attention
9 Blockbuster Drugs Making Their Debut In 2017; Total Revenue Expected To Be $16B By 2021
Article By:
Lorimer Wilson
Read
Tuesday, April 11, 2017 11:56 PM EDT
It is always interesting to see what analysts believe the big new drugs of the year are going to be worth 5 years down the road and Clarivate Analytics has listed the 9 blockbusters their analysts expect to see approved by the FDA this year.
Biotech In A Doldrums: Rallies Interrupted By Geopolitics, Trump Agenda And Flight To Safety
Article By:
Rod Raynovich
Read
Tuesday, April 11, 2017 7:38 PM EDT
Recent geopolitical news has created a backdrop that has discouraged investors in biotech who were already risk averse from drug pricing issues. There has been little momentum over since mid-march with choppy sluggish trading.
AbbVie: Humira Fears Likely Overblown, Strong Total Returns Ahead
Article By:
SureDividend
Read
Tuesday, April 11, 2017 1:54 PM EDT
AbbVie presents a compelling value at today’s prices. The company has grown its adjusted earnings-per-share at a rate of ~15% since the spin-off, and management is expecting growth of around 14% per year going forward.
FDA Keeping A Partial "Hold" On Repros Therapeutics’ Proellex
Article By:
Lorimer Wilson
Read
Monday, April 10, 2017 7:59 PM EDT
The FDA plans to maintain a partial clinical hold on Repros Therapeutics' Proellex so regulators can take extra time in consulting with agency experts on the liver effects spotted in the clinic.
In this article: RPRX
Cytori Announces Proposed Public Offering Of Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Monday, April 10, 2017 6:53 PM EDT
Cytori Therapeutics, Inc. announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by Cytori.
In this article: PSTV
Roche’s Alecensa Trumps Pfizer’s Xalkori As A Frontline Therapy For ALK+ Lung Cancer
Article By:
Lorimer Wilson
Read
Monday, April 10, 2017 6:36 PM EDT
A year after Roche won an accelerated approval for Alecensa as a new drug for treatment-resistant ALK-positive non-small cell lung cancer it has trumped Pfizer’s Xalkori as a frontline therapy, beating out their rival on progression-free survival.
Roche’s Alecensa Finally Tops Pfizer’s Xalkori As A First-Line Treatment In ALK-Positive Lung Cancer
Article By:
Lorimer Wilson
Read
Monday, April 10, 2017 4:59 PM EDT
Roche’s Alecensa topped Pfizer’s Xalkori as a first-line treatment in ALK-positive lung cancer, top-line results from a new trial show, adding to its case for an expanded approval—and for an impending showdown with Novartis in the same setting.
JNJ's Not Pulling The Plug On "Imetelstat" Sends Geron Corp. Shares UP 23% Mid-Morning
Article By:
Lorimer Wilson
Read
Monday, April 10, 2017 11:38 AM EDT
Johnson & Johnson's review of data from two studies of the Geron Corp drug imetelstat has concluded that it warrants continued work and that it is still reserving the right to quit if the data don’t hold up later in the year.
Stock Markets Lining Up For A Major Top Sometime Between August & October 2017
Article By:
Lorimer Wilson
Read
Sunday, April 9, 2017 6:42 PM EDT
We believe markets are lining up for a major top later in 2017, possibly in the August to October time period. There are several patterns we are watching that lead us to this conclusion.
Week In Review: How Trump's Policies Moved Stocks
10 Things Investors Should Know About Corporate Mergers
Article By:
Lorimer Wilson
Read
Saturday, April 8, 2017 6:46 PM EDT
Company executives use buzzwords like "synergies" and "profit acceleration" to tout the virtues of an acquisition but what do these mergers mean for shareholders? Here are some key things you need to know about corporate buying and selling.